Use of BNP and CRP as biomarkers in assessing cardiovascular disease: Diagnosis versus risk

Current Vascular Pharmacology

Volumn 5, Issue 1, 2007, Pages 15-25

  Miller, Virginia M ^a   Redfield, Margaret M ^b   McConnell, Joseph P ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

B type natriuretic peptide; BNP; C reactive protein; Coronary artery disease; CRP; Estrogen; Heart failure; Hormone replacement therapy

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; VASODILATOR AGENT;

ARTERIAL PRESSURE; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DYSPNEA; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; IMMUNOFLUORESCENCE; LIPID PEROXIDATION; OBESITY; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SMOKING; METABOLISM; RISK FACTOR;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 34247142940     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016107779317251     Document Type: Review

References (85)

1. Senni M. Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol 2001; 38: 1277-82.
2. Managala VK, Burnett JC, Jr., Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004; 29: 707-69.
3. Yamamoto K, Burnett JC, Jr., Bermudez EA, Jougasaki M, Bailey KR, Redfield MM. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Cardiac Failure 2000; 6: 194-200.
4. Yamamoto K, Burnett JC, Jr., Jougasaki M, Nishimura RA., Bailey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-94.
5. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. New Engl J Med 1998; 339: 321-28.
6. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC, Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002; 40: 976-82.
7. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90: 254-58.
8. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, et al. Plasma brain natruiretic peptide in assessment of acute dyspnea. Lancet 1994; 343: 440-44.
9. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53.
10. Dao Q, Krishnaswamy P, Kezanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379-85.
11. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New Engl J Med 2002; 347: 161-67.
12. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
13. Villacorta H, Campos A, Duarte N, Martins MV, Mesquite ET. The utility of B-type natriuretic peptide in the diagnosis of heart failure with preserved systolic function in patients presenting to the emergency department with dyspnea. J Cardiac Failure 2002; 8: S28.
14. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106: 416-22.
15. Writing Group for the Women's Health Initiative Investigators. Design of the Women's Health Initiative Clinical Trial and Observational Study. Control Clin Trials 1998; 19: 61-109.
16. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57.
17. Maisel AS, Clopton P, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: Results from the Breathing Not Properly (BNP) multinational study. Am Heart J 2004; 147: 1078-84.
18. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: 1-82.
19. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003; 41: 113-20.
20. Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S, et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular, dysfunction in patients with diabetes. Diabetes Care 2003; 26: 2081-87.
21. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial. J Am Coll Cardiol 2003; 42: 1793-8
22. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls G, Richards M. Plasma amino-terminal B-type natriuretic peptide measured by elecsys 2010 assay in a trial of hormone-guided treatment for heart failure. Clin Chem 2003; 49: 1212-5.
23. Troughton RW, Richards M. B-type natriuretic peptides: Applications for heart failure management in 2005. Int Med J 2005; 35: 377-9
24. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42: 728-135.
25. Kirk V, Bay M, Parner J, Krogsgaard K, Herzog TM, Boesgaard S, et al. N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: Data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Failure 2004; 6: 335-41.
26. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P. Beauvais F, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635-41.
27. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
28. Shrive AK, Cheetham GMT, Holden D, Myles DA, Turnell WG, Volanakis JE, et al. Three dimensional structure of human C-reactive protein. Nat Struct Biol 1996; 3: 346-54.
29. Young B, Gleeson M, Cripps AW. C-reactive protein: A critical review. Pathology 1991; 23: 118-24.
30. Volanakis JE. Human C-reactive protein: Expression, structure, and function. Mol Immunol 2001; 38: 189-97.
31. Claus DR, Osmand AP, Gewurz H. Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med 1976; 87: 120-128.
32. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications. Clin Chem 1997; 43: 52-58.
33. Tracy RP, Psaty BM, Macy E, Bovil EG, Cushman M, Cornell ES, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in elderly subjects. Arterioscler Thromb Vasc Biol 1997; 17: 2167-76.
34. Wilkins J, Gallimore JR, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 1998; 44: 1358-61.
35. Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GDO, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: Age-related values in the adult general population. Clin Chem 2000; 46: 934-38.
36. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Chin Chem 2001; 47: 444-50.
37. McConnell JP, Branum EL, Ballman KV, Lagerstedt SA, Katzmann JA, Jaffe AS. Gender differences in C-reactive protein concentration - Confirmation with two sensitive methods. Clin Chem Lab Med 2002; 40: 56-59.
38. Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population. Am J Epidemiol 2001; 153: 1183-90.
39. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol1999; 19: 893-99.
40. Ridker PM, Hennekens CH, Nader R, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-16.
41. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717-22.
42. Walsh BW, Paul S, Wild RA et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial. J Clin Endocrinol Metab 2000; 85: 214-18.
43. Luyer MDP, Khosla S, Owen WG, Miller VM. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 2000; 86: 3629-34.
44. Walsh B, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001; 88: 825-28.
45. Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri-Gonzaga A, Ramazzotto F, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002; 106: 1224-28.
46. Albert MA, Glynn RJ, Buring JE, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol 2004; 93: 1238-42.
47. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
48. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Part 2. Clin Chem 2001; 47: 418-25.
49. Tracy RP, Kuller LH. C-reactive protein, heart disease risk, and the popular media. Arch Intern Med 2005; 165: 2058-60.
50. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the Am Heart Assoc Circulation 2003; 107: 499-511.
51. Roberts WL, Schwarz EL, Ayanian S, Rifai N. Performance characteristics of a point of care C-reactive protein assay. Clinica Chimica Acta 2001; 314: 255-59.
52. De BK, Smith LG, Owen WE, Roberts WL. Performance characteristics of an automated high-sensitivity C-reactive protein assay on the Dimension RXL analyzer. Clinica Chimica Acta 2002; 323: 151-55.
53. Thompson D, Milford-Ward W, Wincher JT. The value of acute phase protein measurements in clinical practice. Ann Clin Biochem 1992; 29: 123-31.
54. Dahler-Eriksen BS, Lassen JF, Lund ED, Lauritzen T, Brandslund I. C-reactive protein in general practice - how commonly is it used and why? Scand J Prim Health Care 1997; 15: 35-38.
55. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(s), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-85.
56. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease. Prospective analysis from the Women's Health Initiative Observational Study. JAMA 2002; 288: 980-87.
57. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
58. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
59. Danenberg HD, Szalai AJ, Swaminathan RJ, Peng L, Chen Z, Seifert P, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108: 512-15.
60. Wang C-H, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, et al. C-reactive protein upregulates angiotensin type I receptors in vascular smooth muscle. Circulation 2003; 107: 1783-90.
61. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109: 647-55.
62. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8: 3-12.
63. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 420-25.
64. Trayhurn P. The biology of obesity. Proc Nutrition Soc 2005; 64: 31-38.
65. Nash DT. Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: Potential role of statins. J Natl Med Assoc 2005; 97: 1600-07.
66. Ridker PM, Buring JE, Cook NR, Rifai N, C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-97.
67. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis 2005; 183: 308-15.
68. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-79.
69. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002; 105: 15-21.
70. Ridker P, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
71. Ferdinand KC, Clark LT, Watson KE et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol 2006; 97: 229-35.
72. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38.
73. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes. South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002; 106: 1219-23.
74. Gibbs RGJ, Carey N, Davies AH. Chlamydia pneumoniae and vascular disease. Br J Surg 1998; 85: 1191-97.
75. Pietroiusti A, Diomedi M, Silvestrini M, Cupini LM, Luzzi J, Gomez-Miguel MJ, et al. Cytotoxin-associated gene-A-positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation 2002; 106: 580-84.
76. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death. Association with different pathologies. Circulation 2002; 105: 2019-23.
77. Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex, and hormone replacement treatment. Circulation 2000; 101: 1785-91.
78. Pasceri G, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothehial cells. Circulation 2000; 102: 2165-68.
79. Pasceri G, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-34.
80. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
81. Kushner I, Mackiewicz A. Acute phase proteins as disease markers. Disease Markers 1987; 5: 1-11.
82. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med 2006; 166: 357-65.
83. Szalai AJ, McCrory MA. Varied biologic functions of C-reactive protein. Lessons learned from transgenic mice. Immunol Res 2002; 3: 279-87.
84. Folsom AR, Aleksic N, Catellier D, Junega HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J 2002; 144: 233-38.
85. Yeh ETH, Willerson JT. Coming of age of C-reactive protein. Using inflammation markers in cardiology. Circulation 2003; 107: 370-72.